Selected adverse reactions (all grades) that were reported in <10% of patients treated with Inlyta included dizziness (9%), upper abdominal pain (8%), myalgia (7%), dehydration (6%), epistaxis (6%), anemia (4%), hemorrhoids (4%), hematuria (3%), tinnitus (3%), lipase increased (3%), pulmonary embolism (2%), rectal hemorrhage (2%), hemoptysis (2%), deep vein thrombosis (1%), retinal-vein occlusion/thrombosis (1%), polycythemia (1%), transient ischemic attack (1%), and RPLS (<1%).
Table 2 presents the most common laboratory abnormalities reported in ≥10% patients who received Inlyta or sorafenib.
Table 2. Laboratory Abnormalities Occurring in ≥10% of Patients Who Received Inlyta or Sorafenib